Rachel D.
- Country
- France
- Department
- N/A
Research Overview
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Trial of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Trial of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
- Evaluation of Long-term Safety and Tolerability of TAK-861 in Patients with Narcolepsy Type 1
Data & Insights
Has run more than one trial at 40 of 60 partner sites.
Specializations
Sleep Disorders
This investigator specializes in the treatment and research of narcolepsy with cataplexy, focusing particularly on novel therapeutic approaches for Type 1 Narcolepsy.
- Sleep disorder management
- Cataplexy treatment
- Narcolepsy therapeutics
The investigator evaluates long-term safety and tolerability of emerging treatments for sleep disorders.
Clinical Assessment
The investigator utilizes specialized assessment tools including the Epworth Sleepiness Scale (ESS) to evaluate excessive daytime sleepiness in patients.
- Sleep assessment methodologies
- Daytime sleepiness evaluation
- Patient monitoring systems
Their work encompasses comprehensive evaluation of treatment efficacy in sleep disorder patients.
Treatment Innovation
The investigator focuses on developing and evaluating new therapeutic options for neurological sleep disorders, with particular attention to long-term patient outcomes.
- Novel therapeutic approaches
- Safety monitoring
- Treatment effectiveness
Their research includes systematic evaluation of emerging treatments for narcolepsy management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.